[go: up one dir, main page]

DE60310383D1 - Vorbeugung von gewebeadhäsion - Google Patents

Vorbeugung von gewebeadhäsion

Info

Publication number
DE60310383D1
DE60310383D1 DE60310383T DE60310383T DE60310383D1 DE 60310383 D1 DE60310383 D1 DE 60310383D1 DE 60310383 T DE60310383 T DE 60310383T DE 60310383 T DE60310383 T DE 60310383T DE 60310383 D1 DE60310383 D1 DE 60310383D1
Authority
DE
Germany
Prior art keywords
post
operative
adhesions
prevention
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60310383T
Other languages
English (en)
Other versions
DE60310383T2 (de
Inventor
Philippe Koninckx
Peter Carmeliet
Desire Collen
Sanabria Roger Molinas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Thromb X NV
Original Assignee
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Thromb X NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201983A external-priority patent/GB2384428A/en
Priority claimed from GB0202379A external-priority patent/GB2384706A/en
Priority claimed from GB0225128A external-priority patent/GB0225128D0/en
Application filed by Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB, Thromb X NV filed Critical Katholieke Universiteit Leuven
Application granted granted Critical
Publication of DE60310383D1 publication Critical patent/DE60310383D1/de
Publication of DE60310383T2 publication Critical patent/DE60310383T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
DE60310383T 2002-01-29 2003-01-29 Vorbeugung von gewebeadhäsion Expired - Fee Related DE60310383T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0201983 2002-01-29
GB0201983A GB2384428A (en) 2002-01-29 2002-01-29 Inhibitors of HIF
GB0202379A GB2384706A (en) 2002-02-04 2002-02-04 Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation
GB0202379 2002-02-04
GB0225128A GB0225128D0 (en) 2002-10-29 2002-10-29 Laparoscopy and adhesion formation
GB0225128 2002-10-29
PCT/EP2003/000892 WO2003063904A2 (en) 2002-01-29 2003-01-29 Tissue adhesion formation control

Publications (2)

Publication Number Publication Date
DE60310383D1 true DE60310383D1 (de) 2007-01-25
DE60310383T2 DE60310383T2 (de) 2007-09-20

Family

ID=27669901

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310383T Expired - Fee Related DE60310383T2 (de) 2002-01-29 2003-01-29 Vorbeugung von gewebeadhäsion

Country Status (5)

Country Link
US (1) US20050163781A1 (de)
EP (1) EP1482975B1 (de)
AT (1) ATE347908T1 (de)
DE (1) DE60310383T2 (de)
WO (1) WO2003063904A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20050049309A1 (en) * 2003-07-14 2005-03-03 Lynn Kirkpatrick Regulation of HIF protein levels via deubiquitination pathway
US7807814B2 (en) 2003-12-23 2010-10-05 The Trustees Of The University Of Pennsylvania Compositions and methods for combined therapy of disease
US7618947B2 (en) * 2004-08-25 2009-11-17 Isis Pharmaceuticals, Inc. Modulation of HIF-1 beta expression
EP1869085B1 (de) 2005-03-24 2012-03-14 ThromboGenics N.V. Neuer anti-plgf-antikörper
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
CN101868251B (zh) * 2007-08-06 2012-10-10 千寿制药株式会社 含有HIF-1α和HIF-2α表达抑制物质的药物
EP2785739B1 (de) 2011-12-01 2017-03-15 ThromboGenics N.V. Verbesserung eines augendrucksenkungsergebnisses
RU2672377C1 (ru) * 2013-12-18 2018-11-14 СиЭсЭл ЛИМИТЕД Способ лечения ран
US20190031762A1 (en) 2016-03-10 2019-01-31 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
EP3448421B1 (de) * 2016-04-29 2021-11-03 The Board of Trustees of the Leland Stanford Junior University Verfahren und zusammensetzungen zur vorbeugung und behandlung von chirurgischen verklebungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887076A3 (de) * 1997-05-07 1999-03-31 Saturnus A.G. Verhinderung von Gewebeverklebung und ein dafür vorgesehenes endoskopisches System zum Aufblasen einer Körperhöhle
TW557297B (en) * 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
EP1676845B1 (de) * 1999-11-05 2008-06-11 AstraZeneca AB Neue Quinazolin-Derivate
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation

Also Published As

Publication number Publication date
DE60310383T2 (de) 2007-09-20
WO2003063904A3 (en) 2004-01-15
US20050163781A1 (en) 2005-07-28
WO2003063904A2 (en) 2003-08-07
EP1482975A2 (de) 2004-12-08
EP1482975B1 (de) 2006-12-13
ATE347908T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
DE60310383D1 (de) Vorbeugung von gewebeadhäsion
ATE361300T1 (de) Derivate von heteroarylnitrilverbindungen
GB0223040D0 (en) Therapeutic compounds
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
NO20055305D0 (no) Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ATE464889T1 (de) Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BRPI0311323B8 (pt) composto inibidor de c-aril glicosídeo sglt2, composição farmacêutica e combinação
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
ATE404204T1 (de) Behandlung und vorbeugung von adhesionen
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
ATE384058T1 (de) Thiazolderivate
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee